2-氨基-6-苄基-1H-嘧啶-4-酮 | 717-88-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基-6-苄基-1H-嘧啶-4-酮
• 中文别名: 2-氨基-(6苯甲基)-4(3H)嘧啶酮
• 英文名称: 2-Amino-4-benzyl-pyrimidinol-(6)
• 英文别名: 2-amino-6-benzyl-3H-pyrimidin-4-one；2-amino-6-benzylpyrimidin-4(1H)-one；2-amino-4-benzyl-1H-pyrimidin-6-one
• CAS: 717-88-4
• 化学式: C₁₁H₁₁N₃O
• 分子量: 201.228
• InChiKey: ICVOELCHCKJETJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氨基-6-苄基-1H-嘧啶-4-酮 在 四乙基氯化铵 、 N,N-二甲基苯胺 、 三乙胺 、 三氯氧磷 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 16.33h， 生成
  参考文献：
  名称：

  Discovery and SAR of 6-Alkyl-2,4-diaminopyrimidines as Histamine H₄ Receptor Antagonists

  摘要：

  This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. Building on our SAR studies of saturated derivatives from the indole carboxamide series, typified by JNJ 7777120, and incorporating knowledge from the tricyclic pyrimidines led us to the 6-alkyl-2,4-diaminopyrimidine series. A focused medicinal chemistry effort delivered several 6-alkyl-2,4-diaminopyrimidines that behaved as antagonists at both the human and rodent H4 receptor. Further optimization led to a panel of antagonists that were profiled in animal models of inflammatory disease. On the basis of the preclinical profile and efficacy in several animal models, JNJ 39758979 was selected as a clinical candidate; however, further development was halted during phase II because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.

  DOI：

  10.1021/jm401727m
• 作为产物：
  描述：

  3-氧代-4-苯基丁酸甲酯 、 盐酸胍 在 potassium tert-butylate 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 2-氨基-6-苄基-1H-嘧啶-4-酮
  参考文献：
  名称：

  [EN] CHEMICAL COMPOUNDS
  [FR] COMPOSÉS CHIMIQUES

  摘要：

  本发明涉及取代吲唑衍生物。具体而言，本发明涉及根据公式I的化合物：其中R1-R6和X在此定义。本发明的化合物是PDK1的抑制剂，可用于治疗由组成性激活的ACG激酶（如癌症，特别是白血病、乳腺癌、结肠癌和肺癌）引起的疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。

  公开号：

  WO2010120854A1

文献信息

• Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
  申请人：Biofrontera Pharmaceuticals AG

  公开号：EP1321169A1

  公开（公告）日：2003-06-25

  The present invention relates to the use of (S)-α-fluoromethylhistidine and esters and pharmaceutically acceptable salts thereof in combination with a serotonin receptor antagonist or a pharmaceutically acceptable salt thereof as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a serotonin receptor antagonist and/or a histamine receptor antagonist.

  本发明涉及使用(S)-α-氟甲基组氨酸及其酯和药学上可接受的盐与5-羟色胺受体拮抗剂或其药学上可接受的盐结合作为药物，并用于制造一种治疗可通过使用5-羟色胺受体拮抗剂和/或组胺受体拮抗剂进行缓解的疾病状态的药物。
• Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
  申请人：——

  公开号：US20030008887A1

  公开（公告）日：2003-01-09

  A method for inhibiting sexual transmission of HIV comprising topically applying to the skin or epithelial tissue of a human a composition comprising a non-nucleoside reverse transcriptase inhibitor (“NNRTI”) that is able to inhibit viral replication for periods exceeding 12, 24, or even 36 days, at concentrations below even 10 &mgr;M. In one embodiment the NNRTI is a dihydro-alkyloxy-benzyl-oxopyrimidine (DABO).

  一种抑制HIV性传播的方法，包括将一种含有非核苷类反转录酶抑制剂（“NNRTI”）的组合物局部涂抹于人体的皮肤或上皮组织上，该NNRTI能够在浓度低于10 &mgr;M的情况下抑制病毒复制，持续时间超过12、24或36天。在一种实施方式中，NNRTI是一种二氢烷氧基苯基嘧啶（DABO）。
• [EN] ARYL PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES D'ARYL PYRIMIDINE
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：WO1997044326A1

  公开（公告）日：1997-11-27

  (EN) The present invention is directed to pyrimidine derivatives, and pharmaceutically acceptable salts and $i(N)-oxides thereof, which exhibit useful pharmacological properties, in particular use as selective 5HT2B-antagonists, their preparation, pharmaceutical compositions comprising them and their use in the treatment of various diseases, especially migraine. The invention is also directed to formulations and methods for treatment.(FR) Cette invention a trait à des dérivés d'aryl pyrimidine ainsi qu'à leurs sels et à leurs $i(N)-oxydes, acceptables d'un point de vue pharmaceutique. Ces substances, qui font montre d'utiles propriétés pharmacologiques, sont notamment efficaces comme antagonistes sélectifs de 5HT2B. L'invention a également trait à la préparation de ces substances, à des compositions pharmaceutiques les contenant, ainsi qu'à leur utilisation dans le traitement de troubles divers, de la migraine notamment. Elle concerne, de surcroît, des formulations et des méthodes thérapeutiques.

  本发明涉及嘧啶衍生物及其药学上可接受的盐和$i(N)$-氧化物，具有有用的药理学特性，特别是作为选择性5HT2B拮抗剂的用途，其制备，包含它们的制药组合物以及它们在治疗各种疾病，尤其是偏头痛方面的用途。本发明还涉及治疗方法和制剂。
• Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4- oxopyrimidines
  申请人：Idenix Pharmaceuticals, Inc.

  公开号：US20030225114A1

  公开（公告）日：2003-12-04

  A method for inhibiting sexual transmission of HIV comprising topically applying to the skin or epithelial tissue of a human a composition comprising a non-nucleoside reverse transcriptase inhibitor (“NNRTI”) that is able to inhibit viral replication for periods exceeding 12, 24, or even 36 days, at concentrations below even 10 &mgr;M. In one embodiment the NNRTI is a dihydro-alkyloxy-benzyl-oxopyrimidine (DABO).

  一种抑制艾滋病毒性传播的方法，包括在人的皮肤或上皮组织局部施用一种组合物，该组合物包含一种非核苷类逆转录酶抑制剂（"NNRTI"），它能够抑制病毒复制超过 12、24 或甚至 36 天，浓度甚至低于 10 &mgr;M。在一个实施方案中，NNRTI 是一种二氢-烷氧基-苄基-氧代嘧啶（DABO）。
• Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040092539A1

  公开（公告）日：2004-05-13

  The invention concerns novel substituted 6-benzyl-4-oxopyrimnidines of general formula (A). These compounds inhibit reverse transcriptase encoded by human immunodeficiency virus (HIV) or pharmaceutically acceptable salts thereof, and find their application in the prevention and treatment of HIV infection and the treatment of the resulting acquired immune deficiency syndrome (AIDS). Pharmaceutical compositions containing the compounds and a method of use of the present compounds and other agents for the treatment of AIDS and viral infection by HIV are also envisaged. 1

  本发明涉及通式（A）的新型取代 6-苄基-4-氧代嘧啶。这些化合物可抑制由人类免疫缺陷病毒（HIV）编码的逆转录酶或其药学上可接受的盐类，可用于预防和治疗 HIV 感染以及治疗由此引起的获得性免疫缺陷综合征（AIDS）。还设想了含有本发明化合物的药物组合物以及本发明化合物和其他制剂治疗艾滋病和 HIV 病毒感染的使用方法。 1